Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis

Table 2 TNF-RI A36G single nucleotide polymorphism genotype frequencies and sTNFR levels

Genotype	n (%)	sTNF-RI (pg/ml)	sTNF-RII (pg/ml)
Early RA
AA	41 (39.8)	1,543 ± 597	4,435 ± 1,898
AG	50 (48.5)	1,426 ± 629	4,302 ± 1,672
GG	12 (11.7)	1,303 ± 447	4,566 ± 1,490
Established RA
AA	48 (31.8)	1,827 ± 758	5,740 ± 1,942
AG	70 (46.4)	1,688 ± 674	5,475 ± 2,020
GG	33 (21.8)	1,757 ± 559	5,857 ± 2,393

Shown are tumor necrosis factor receptor I (TNF-RI) A36G single nucleotide polymorphism genotype frequencies and soluble tumor necrosis factor receptor (sTNFR) levels in rheumatoid arthritis (RA) patients with early (n = 103) and established (n = 151) disease. sTNFR levels are expressed as the mean ± standard deviation. No significant differences in sTNFR levels were found between any of the genotypes in either population. sTNF-RII, soluble tumor necrosis factor receptor II.

ISSN: 1478-6362